Published on December 7, 2009 at 8:10 AM
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I
weekly-dosing clinical trial of brentuximab vedotin (SGN-35), an
antibody-drug conjugate (ADC), including multiple complete and partial
remissions in patients with relapsed or refractory Hodgkin lymphoma or
systemic anaplastic large cell lymphoma (ALCL). The data were presented
at the American Society of Hematology (ASH) 51st Annual
Meeting being held in New Orleans, Louisiana.
“The encouraging data from this phase I trial in heavily pretreated
lymphoma patients are consistent with the objective response rate
observed in our every three week dosing phase I trial, and provide us
with additional understanding about the single-agent dose, schedule and
tolerability profile of brentuximab vedotin when administered weekly,”
said Clay B. Siegall, Ph.D., President and Chief Executive Officer of
Seattle Genetics. “These data reinforce our belief that brentuximab
vedotin could play an important role in the treatment of Hodgkin and
other CD30-positive lymphomas, and we are focused on bringing this ADC
to patients as rapidly as possible. We expect data from our fully
enrolled pivotal trial for relapsed and refractory Hodgkin lymphoma in
the second half of 2010. If the data are supportive, we intend to use
this trial as the basis for a new drug application (NDA) in the first
half of 2011. We are also investigating the potential of brentuximab
vedotin in other therapeutic settings, including an ongoing phase II
single-agent trial for systemic ALCL and planned trials in earlier lines
of therapy, such as combination regimens for Hodgkin lymphoma.”
SOURCE Seattle Genetics
086fae0e-6a96-434a-8411-e1e4ddc0e182|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Autoimmune Disease, Biotechnology, Brentuximab Vedotin, Cancer, Cell, Chemotherapy, Dacarbazine, Genetics, Hematology, Lymphoma, Monoclonal Antibody, Nausea, Neuropathy, New Drug Application, Oncology, Peripheral Neuropathy, Stem Cell, Systemic Anaplastic Large Cell Lymphoma, Transplant, Vinblastine